期刊文献+

Clinical characteristics and pharmacokinetics of PAXLOVID in COVID-19 patients with hematological tumor

原文传递
导出
摘要 To the editor:Since the onset of COVID-19,several new treatments have been studied,but only a few have received approval for clinical use.However,a challenge we still face is that in real-world medical practice,the patient population may differ from those in clinical trials.For instance,prolonged viral elimination has become an issue in immunocompromised patients[1,2]
出处 《Medical Review》 2024年第2期169-171,共3页 医学评论(英文)
基金 Peking University Third Hospital,BYSYDL2023001-05,BYSYDL2023001-08,BMU2023XY019.
  • 相关文献

参考文献1

二级参考文献1

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部